Lung cancer is the second most diagnosed cancer and the leading cause of cancer-related death worldwide. There are two main types of lung cancer: non-small cell lung cancer, which accounts for 80-85 percent of lung cancer cases, and small cell lung cancer, which accounts for 10-15 percent of cases. While the number of new lung cancer cases continues to decrease, largely due to smoking cessation efforts, avoidance of risk factors, and advances in early detection and treatment, lung cancer continues to make up nearly 25 percent of all cancer deaths.
Fragmentation in the U.S. healthcare system can impede consistent and equitable access to lung cancer care. Gaps in the quality of lung cancer care delivery persists in certain patient populations resulting in suboptimal outcomes. As such, ACCC continues to focus its efforts on developing comprehensive resources for multidisciplinary cancer care teams and patient advocates to better support patients with lung cancer, eliminate disparities related to access and treatment, and access best practice recommendations for improved quality care.
ACCC offers diverse educational resources, digital tools and publications that address the complex challenges in delivering quality lung cancer care.
ACCC conducted patient and provider surveys to determine how to raise awareness about best practices in treating patients with small cell lung cancer. The surveys were used to identify and better understand the gaps and potential disconnects in the patient/provider relationship.
Through the development and facilitation of both patient and provider surveys, ACCC will highlight the patient experience, dispel myths and misconceptions, breakdown guideline-discordant treatment plans, and identify and uncover barriers, gaps, and challenges to obtaining optimal care.
Lung cancer remains the leading cause of cancer-related death in the United States, accounting for more fatalities than colorectal and pancreatic cancer combined. One of the keys to improving clinical outcomes lies in early detection and intervention, especially for incidental lung nodules, which could be an early indicator of lung cancer.
ACCC recognizes August 1st as World Lung Cancer Day through its past Innovator Award winners.
ACCCBuzz spotlights University of Colorado Cancer Center, one of the recipients of the 2024 ACCC Innovator Award.
Highlights from a LUNGevity Lung Cancer Precision Medicine Summit that addressed critical issues surrounding biomarker testing in non-small cell lung cancer.
LUNGevity invited ACCC and other stakeholders across the oncology world to Washington DC, for their second Health Equity Summit on Tuesday, March 12.
ACCC recognizes April as National Cancer Prevention and Early Detection Month.
We take a look at how the COVID-19 pandemic has impacted lung screenings across the country and how oncology teams are adapting their outreach and education to reach as many people as possible.
We mark the beginning of Lung Cancer Awareness Month by looking at the present landscape for the diagnosis and treatment of one of the most common cancers in the world.
Hear from Wendi Waugh, Director of Cancer Services, Southern Ohio Medical Center, as she discusses the implementation of a process improvement plan with a focus on enhancing care for patients with advanced NSCLC.
Despite the high mortality rate of lung cancer, screening eligible, high-risk patients remains a challenge. Learn about the implementation of a lung cancer screening program in a community setting that significantly improved early detection and outcomes.
A 2020 ACCC Innovator Award Winner discusses the growth and progress on her patient education tool, Pocket Nodules, and the creation of a similar tool designed for patients with breast cancer.
Presented at the 2021 ASCO Quality Care Symposium, September 24 - 25, 2021.
UCHealth used AI to create a safety net for patients with incidental lung nodules by equipping its technology to evaluate radiology interpretations, identify incidental lung nodules and their characteristics, and triage patients based on risk level.